Sign Up to like & get
recommendations!
0
Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05305-w
Abstract: PurposeMetastatic triple-negative breast cancer (TNBC) is a phenotypic breast cancer subgroup with a very poor prognosis, despite standard treatments. Combined twice-weekly iniparib and gemcitabine/carboplatin (GC+tw-iniparib) showed benefit over gemcitabine/carboplatin in a randomized phase II trial,…
read more here.
Keywords:
gemcitabine carboplatin;
twice weekly;
iniparib;
breast cancer ... See more keywords